CA1077840A - Antigene tumoral et procede de preparation - Google Patents
Antigene tumoral et procede de preparationInfo
- Publication number
- CA1077840A CA1077840A CA277,457A CA277457A CA1077840A CA 1077840 A CA1077840 A CA 1077840A CA 277457 A CA277457 A CA 277457A CA 1077840 A CA1077840 A CA 1077840A
- Authority
- CA
- Canada
- Prior art keywords
- tumor
- supernatant
- tumor cells
- suspension
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 50
- 239000000427 antigen Substances 0.000 title claims abstract description 34
- 102000036639 antigens Human genes 0.000 title claims abstract description 34
- 108091007433 antigens Proteins 0.000 title claims abstract description 34
- 238000000034 method Methods 0.000 title claims abstract description 21
- 230000008569 process Effects 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 27
- 239000006228 supernatant Substances 0.000 claims abstract description 17
- 210000004027 cell Anatomy 0.000 claims abstract description 16
- 150000001875 compounds Chemical class 0.000 claims description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 11
- 239000000725 suspension Substances 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 229950004354 phosphorylcholine Drugs 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 claims description 5
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 4
- 238000004062 sedimentation Methods 0.000 claims description 3
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoserine Chemical compound OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical class CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 5
- 230000001024 immunotherapeutic effect Effects 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 description 11
- 239000013049 sediment Substances 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 201000000050 myeloid neoplasm Diseases 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 3
- PPQNQXQZIWHJRB-UHFFFAOYSA-N Methylcholanthrene Chemical compound C1=CC=C2C3=CC4=CC=C(C)C(CC5)=C4C5=C3C=CC2=C1 PPQNQXQZIWHJRB-UHFFFAOYSA-N 0.000 description 3
- 239000007975 buffered saline Substances 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 208000037841 lung tumor Diseases 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000005373 porous glass Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
- JVGJWHQKHATXLD-UHFFFAOYSA-N 1-methyl-1,2-dihydrobenzo[j]aceanthrylene Chemical compound C1=CC=C2C(C=C3C=CC=C4CC(C5=C43)C)=C5C=CC2=C1 JVGJWHQKHATXLD-UHFFFAOYSA-N 0.000 description 1
- 238000011735 C3H mouse Methods 0.000 description 1
- 241000237074 Centris Species 0.000 description 1
- 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 101710165590 Mitochondrial pyruvate carrier 1 Proteins 0.000 description 1
- 102100024828 Mitochondrial pyruvate carrier 1 Human genes 0.000 description 1
- 238000011785 NMRI mouse Methods 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 101710101695 Probable mitochondrial pyruvate carrier 1 Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940046545 animal allergen extract Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 244000221110 common millet Species 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002635 electroconvulsive therapy Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19762619715 DE2619715A1 (de) | 1976-05-04 | 1976-05-04 | Tumor-antigen und verfahren zu dessen herstellung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1077840A true CA1077840A (fr) | 1980-05-20 |
Family
ID=5977057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA277,457A Expired CA1077840A (fr) | 1976-05-04 | 1977-05-03 | Antigene tumoral et procede de preparation |
Country Status (17)
| Country | Link |
|---|---|
| JP (1) | JPS52134011A (fr) |
| AT (1) | AT362497B (fr) |
| AU (1) | AU517395B2 (fr) |
| BE (1) | BE854269A (fr) |
| CA (1) | CA1077840A (fr) |
| DE (1) | DE2619715A1 (fr) |
| DK (1) | DK194477A (fr) |
| FR (1) | FR2391733A1 (fr) |
| GB (1) | GB1575545A (fr) |
| IE (1) | IE44943B1 (fr) |
| IL (1) | IL51989A (fr) |
| IT (1) | IT1074325B (fr) |
| LU (1) | LU77245A1 (fr) |
| NL (1) | NL7704724A (fr) |
| NZ (1) | NZ183980A (fr) |
| SE (1) | SE7705070L (fr) |
| ZA (1) | ZA772648B (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4551532A (en) * | 1980-05-08 | 1985-11-05 | Takeda Chemical Industries, Ltd. | Ethylene glycol derivatives having anti-protozoan, anti-fungal and anti-tumor activity |
| US4444766A (en) * | 1980-10-21 | 1984-04-24 | Boehringer Mannheim Gmbh | Sulfur-containing phospholipid compounds and therapeutic compositions |
| JPS5772914A (en) | 1980-10-22 | 1982-05-07 | Takeda Chem Ind Ltd | Antitumor agent |
| JPS58138383A (ja) * | 1982-02-13 | 1983-08-17 | Nippon Shinyaku Co Ltd | 生理活性物質の製法 |
| US4562179A (en) * | 1982-04-19 | 1985-12-31 | Fujisawa Pharmaceutical Co., Ltd. | Phospholipid derivatives, and pharmaceutical composition of the same |
| JPS5933223A (ja) * | 1982-08-20 | 1984-02-23 | Koken Kk | 人の悪性腫瘍細胞増殖抑制剤 |
| JPS6081194A (ja) * | 1983-10-11 | 1985-05-09 | Takeda Chem Ind Ltd | ケトアルキルリン脂質 |
| JP2561478B2 (ja) * | 1986-07-22 | 1996-12-11 | 武田薬品工業株式会社 | グリセリン誘導体 |
| US5030733A (en) * | 1987-07-23 | 1991-07-09 | Hoechst-Roussel Pharmaceticals Incorporated | Hydroxy-, alkoxy- and benzyloxy-substituted phospholipids |
| US5145844A (en) * | 1987-07-23 | 1992-09-08 | Hoechst-Roussel Pharmaceuticals Incorporated | Methods of using hydroxy-, alkoxy- and benzyloxy-substituted phospholipids to treat phospholipase A2 -mediated conditions and to alleviate pain |
| US5036152A (en) * | 1988-03-10 | 1991-07-30 | Hoechst-Roussel Pharmaceuticals Incorporated | Alkoxycarbonylalkylphospholipids and alkylaminocarbonylalkylphospholipids |
| US4888328A (en) * | 1988-03-10 | 1989-12-19 | Hoeschst-Roussel Incorporated | Alkoxycarbonylalkylphospholipids and alkylaminocarbonylalkylphospholipids |
| DE3906952A1 (de) * | 1989-03-04 | 1990-09-06 | Boehringer Mannheim Gmbh | (3-(c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)6(pfeil abwaerts)-c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)8(pfeil abwaerts))alkansulfinyl- und sulfonyl-2-methoxymethyl-propyl)-(2-trimethylammonio-ethyl) phosphate, verfahren zu deren herstellung diese verbindungen enthaltende arzneimittel |
-
1976
- 1976-05-04 DE DE19762619715 patent/DE2619715A1/de not_active Withdrawn
-
1977
- 1977-04-29 NL NL7704724A patent/NL7704724A/xx not_active Application Discontinuation
- 1977-05-02 IT IT23093/77A patent/IT1074325B/it active
- 1977-05-02 SE SE7705070A patent/SE7705070L/xx unknown
- 1977-05-02 IL IL51989A patent/IL51989A/xx unknown
- 1977-05-02 NZ NZ183980A patent/NZ183980A/xx unknown
- 1977-05-03 AT AT313277A patent/AT362497B/de not_active IP Right Cessation
- 1977-05-03 CA CA277,457A patent/CA1077840A/fr not_active Expired
- 1977-05-03 AU AU24818/77A patent/AU517395B2/en not_active Expired
- 1977-05-03 LU LU77245A patent/LU77245A1/xx unknown
- 1977-05-03 DK DK194477A patent/DK194477A/da not_active Application Discontinuation
- 1977-05-03 GB GB18430/77A patent/GB1575545A/en not_active Expired
- 1977-05-03 IE IE887/77A patent/IE44943B1/en unknown
- 1977-05-04 BE BE177279A patent/BE854269A/fr not_active IP Right Cessation
- 1977-05-04 JP JP5194377A patent/JPS52134011A/ja active Pending
- 1977-05-04 FR FR7713521A patent/FR2391733A1/fr active Granted
- 1977-05-05 ZA ZA00772648A patent/ZA772648B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NL7704724A (nl) | 1977-11-08 |
| IT1074325B (it) | 1985-04-20 |
| DE2619715A1 (de) | 1977-11-24 |
| IL51989A0 (en) | 1977-07-31 |
| BE854269A (fr) | 1977-11-04 |
| JPS52134011A (en) | 1977-11-09 |
| AT362497B (de) | 1981-05-25 |
| IE44943L (en) | 1977-11-04 |
| SE7705070L (sv) | 1977-11-05 |
| DK194477A (da) | 1977-11-05 |
| ZA772648B (en) | 1978-04-26 |
| IL51989A (en) | 1980-01-31 |
| FR2391733B1 (fr) | 1980-03-07 |
| IE44943B1 (en) | 1982-05-19 |
| NZ183980A (en) | 1980-04-28 |
| LU77245A1 (fr) | 1977-12-13 |
| AU2481877A (en) | 1978-11-09 |
| ATA313277A (de) | 1980-10-15 |
| GB1575545A (en) | 1980-09-24 |
| FR2391733A1 (fr) | 1978-12-22 |
| AU517395B2 (en) | 1981-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1077840A (fr) | Antigene tumoral et procede de preparation | |
| JP3631496B2 (ja) | 樹状細胞刺激因子 | |
| JP2003511398A (ja) | 移植における免疫応答の予防および処置に用いる抑制細胞 | |
| Pilch et al. | Transfer of tumor immunity with ribonucleic acid | |
| JP2016539635A (ja) | 抗原特異的調節性ｔ細胞の誘導方法 | |
| CA1280693C (fr) | Purification des antigenes de b. pertussis | |
| Ferguson et al. | The immune response and the eye. II. The nature of T suppressor cell induction in anterior chamber-associated immune deviation (ACAID). | |
| US4788058A (en) | B. pertussis vaccine production using carbodiimides | |
| EP0080021B1 (fr) | Vaccin combiné à base d'haemophilus influenzae type B et d'un élément de la membrane externe de bordetella pertussis | |
| JP3059482B2 (ja) | 大型多価免疫原 | |
| US4220638A (en) | Antigenic complex from N. Gonorrhoeae | |
| US4009257A (en) | Preparation of immunosuppressive materials | |
| Kreier | The isolation and fractionation of malaria-infected cells | |
| Jureziz et al. | Transfer of the delayed hypersensitivity skin reaction in the guinea pig using RNA-treated lymphoid cells | |
| JPH0834742B2 (ja) | 百日せき内毒素の除去法，百日せきトキソイドおよびその製造法 | |
| US4001080A (en) | Production of immunological materials | |
| US4288557A (en) | Antigenic complex from N. gonorrhoeae | |
| FI63674B (fi) | Foerfarande foer isolering och rening av immunologiskt aktivt polyribosylribitolfosfat | |
| Baldwin et al. | Isolation of membrane-associated tumour-specific antigens from rat hepatomas induced by aminoazo dye | |
| Rollins et al. | The influence of glucocorticoids on survival and growth of allografted tumors in the anterior eye chamber of leopard frogs | |
| EP0002645B1 (fr) | Complexe antigénique de neisseria gonorrhoeae, procédé et vaccin | |
| Singh et al. | Effect of xenogeneic immune RNA on normal human lymphocytes against human osteosarcoma cells in vitro | |
| EP0283443A2 (fr) | Procédé d'extraction d'antigènes membranaires ayant des propriétés immunogènes à partir de cellules néoplastiques humaines et produits ainsi obtenus | |
| Jewell et al. | Isolation of parietal cells from guinea-pig gastric mucosa and the immunological characterization of their antigenic structure. | |
| Mikalsen et al. | Recovery of activity and molecular forms of cholinesterase in different animal species following irreversible cholinesterase inhibition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |